Docetaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer / 대한내과학회지

ABSTRACT

BACKGROUND: We evaluated the efficacy and toxicity of docetaxel plus cisplatin combination as first-line chemotherapy for advanced gastric cancer. METHODS: Patients with metastatic or recurrent gastric adenocarcinoma, performance score disease by chemotherapy received up to nine cycles of docetaxel (75 mg/m2, day 1) and cisplatin (60 mg/m2, day 1) every 3 weeks. Response to treatment was assessed every three cycles.

RESULTS:

Thirty-six patients were enrolled in this study. The overall response rate was 44.4% (95% confidence interval; 27.4~61.5%) and median time to progression was 164 days (95% confidence interval; 78~249 days). The median overall survival of all enrolled patients was 287 days (95% confidence interval 162~412 days). Grade 3/4 neutropenia was occurred in 7 patients (19.4%) and febrile neutropenia was observed in 6 patients (16.7%).

CONCLUSION:

Docetaxel plus cisplatin combination as first-line chemotherapy in patients with advanced gastric cancer was effective and tolerable.